2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
250
Carcinoma, Non-Small-Cell Lung
86
Carcinoma, Renal Cell
62
Neoplasm Metastasis
53
Neoplasms
51
Prostatic Neoplasms
35
Lung Neoplasms
32
Uveal Melanoma
29
Pancreatic Neoplasms
28
Carcinoma, Hepatocellular
25
Brain Neoplasms
24
Colorectal Neoplasms
23
Sarcoma
22
Breast Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
18
Small Cell Lung Carcinoma
18
Kidney Neoplasms
18
Skin Neoplasms
17
Diabetes Mellitus, Insulin-Dependent, 12
17
Carcinoma, Transitional Cell
17
Ovarian Neoplasms
15
Urinary Bladder Neoplasms
14
Triple Negative Breast Neoplasms
14
Mesothelioma
13
Glioblastoma
13
Uterine Cervical Neoplasms
12
Recurrence
12
Multiple Myeloma
11
Lymphoma
11
Clear-cell metastatic renal cell carcinoma
11
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Oncolytic Virotherapy
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Bevacizumab
2
valrubicin
1
thymoglobulin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Tenofovir
1
Rituximab
1
Radiotherapy, Intensity-Modulated
1
Papillomavirus Vaccines
1
Nimorazole
1
Mitomycin
1
Lamivudine
1
Kidney Transplantation
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Gemcitabine
1
Gels
1
Fluorescent Antibody Technique
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Virus Diseases
×
Ipilimumab
×
Clear all
NCT03408587
2023-05-06
CLEVER
Viralytics
Phase 1
Completed
11 enrolled